A Clinical Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of [225Ac]Ac-PSMA-XT Injection in Patients With Metastatic Castration-resistant Prostate Cancer

NCT ID: NCT07135102

Last Updated: 2025-08-24

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-10-14
• Study Completion Date: 2027-06-01

Brief Summary

The purpose of this study is to determine the safety and efficacy of 225Ac -labeled PSMA ligand(PSMA-XT) in the treatment of mCRPC

Conditions

Metastatic Castration-Resistant Prostate Cancer Patients

Study Design

• Allocation Method: NA
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

225Ac-PSMA-XT treatment

Group Type: EXPERIMENTAL

225Ac-PSMA-XT

Intervention Type: DRUG

Patients will receive 225Ac-PSMA-XT administration at an interval of 6 weeks between each dose.

Interventions

225Ac-PSMA-XT

Patients will receive 225Ac-PSMA-XT administration at an interval of 6 weeks between each dose.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. have the ability to understand and sign an approved informed consent form (ICF).

2. >= 18 years old.

3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

4. have a life expectancy >6 months.

5. have histological, pathological, and/or cytological confirmation of prostate cancer.

6. PSMA Positron Emission Tomography (PET)/Computed Tomography (CT) scan positive

7. have a castrate level of serum/plasma testosterone (<50 ng/dL or <1.7 nmol/L).

8. have received at least one NAAD (such as enzalutamide and/or abiraterone)； patients must have been previously treated undergone at least 1-2 prior taxane-based chemotherapy regimens or be unsuitable for taxane therapy (unsuitability includes contraindications, investigator-determined ineligibility, or patient refusal) in mCRPC stage.

9. progressive mCRPC.

10. have adequate organ function。

11. Subjects of childbearing potential voluntarily use an effective method of contraception, such as condoms, oral or injectable contraceptives, Intra-uterine device（IUD）,etc., during treatment and within 6 months of the last use of the trial drug.

Exclusion Criteria

1. Previous treatment with any of the following within 6 months of enrollment: Strontium-89, Samarium-153, Rhenium-186, Rhenium-188, Radium-223, hemi-body irradiation. Previous PSMA-targeted radioligand therapy is not allowed.

Known other malignancies.

2. Any systemic anti-cancer therapy (e.g. chemotherapy, immunotherapy or biological therapy within 28 days prior to day of enrollment.

3. Known hypersensitivity to the components of the study therapy or its analogs.

4. A superscan as seen in the baseline bone scan.

5. Patients with a history of Central Nervous System (CNS) metastases.

6. Uncontrolled, intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, cardiac arrhythmia, or other severe complications.

• Minimum Eligible Age: 18 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: No

Sponsors

Xiaorong Sun

OTHER

Sponsor Role: lead

Responsible Party

Xiaorong Sun

Director of Nuclear Medicine Department

Responsibility Role: SPONSOR_INVESTIGATOR

Locations

Cancer Hospital of Shandong First Medical University

Jinan, Shandong, China

Site Status: RECRUITING

Countries

China

Facility Contacts

Xiaorong Sun

Role: primary

xrsun@sdfmu.edu.cn

0531-67626287

Other Identifiers

SDZLEC2024-365-01

Identifier Type: -

Identifier Source: org_study_id